| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -7,751 | -6,954 | -5,399 | -8,877 |
| Stock-based compensation expense | 151 | 47 | 55 | 559 |
| Depreciation and amortization | 454 | NaN | NaN | NaN |
| Fair value of common stock issued to consultants for services | 514 | NaN | NaN | 0 |
| Paid-in-kind interest expense on promissory note | 40 | NaN | 100 | NaN |
| Depreciation and amortization | NaN | 442 | 384 | 483 |
| Accounts receivable, | 188 | -553 | 501 | 269 |
| Non-cash interest expense on promissory note | NaN | NaN | NaN | 100 |
| Operating lease liabilities, net | 18 | 129 | -7 | -67 |
| Prepaid expenses and other current assets | 166 | 209 | -130 | -98 |
| Deposits | 26 | 19 | 16 | -64 |
| Accounts payable | 318 | -424 | 340 | 608 |
| Accrued expenses | 125 | 3,303 | 442 | -127 |
| Other liabilities | 385 | -521 | 358 | 646 |
| Fair value of warrants issued for services | NaN | NaN | NaN | 0 |
| Contract liability | 16 | -59 | 53 | -508 |
| Net cash used in operating activities | -6,010 | -3,812 | -4,161 | -7,290 |
| Payment for acquisition, net of excess cash of 865 | NaN | NaN | 0 | 5,135 |
| Acquisitions of property and equipment | 18 | 1,531 | -83 | 893 |
| Cash paid for acquisition of scn | NaN | 5,185 | NaN | NaN |
| Net cash used in investing activities | -18 | -1,581 | 83 | -6,028 |
| Proceeds from issuance of common stock | 342 | 2,801 | 2,428 | 347 |
| Proceeds from issuance of debt | 1,400 | 1,448 | -417 | 9,642 |
| Proceeds from issuance of warrants | 567 | 0 | 1,699 | NaN |
| Proceeds from issuance of pre-funded warrants | 68 | 0 | 0 | 609 |
| Proceeds from exercise of warrants | 4,639 | 0 | -833 | 1,699 |
| Payments for issuance costs | 487 | 0 | 0 | 837 |
| Reduction of debt liability | 309 | NaN | 97 | NaN |
| Reduction of finance lease liability | 14 | 11 | 17 | NaN |
| Net cash provided by financing activities | 6,109 | 4,335 | 2,763 | 11,460 |
| Net increase (decrease) in cash and cash equivalents | 81 | -1,058 | -1,315 | -1,858 |
| Cash and cash equivalents at beginning of year | 2,029 | 3,087 | 6,260 | NaN |
| Cash and cash equivalents at end of year | 2,110 | 2,029 | 3,087 | NaN |
Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. (VVOS)